Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
Save to Existing Project
Save to a New Project
Non Pungent TRPV1 Agonist as Topical Analgesics for Neuropathic Pain_Medifron_DBT
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Non pungent TRPV1 agonist as topical analgesics for neuropathic pain...
Contact Heajin Jung
Email me a copy of this message
• TRPV1 partial agonist • Agonism mediated pain signal blocking

1. Summary

• TRPV1 is non selective ion channel with a preference for Ca2+.

• TRPV1 function as neuronal membrane recognition site for proton, heat, and irritant compounds such as capsaicin (CAP), resiniferatoxin (RTX).

• TRPV1 expressed exclusively by primary sensory neurons involved in nociception and neurogenic inflammation

• By TRPV1 functional modulation, neuropathic pain can be controlled.

• MDFR series compounds from Medifron_DBT have broad range analgesic effect on inflammatory pain through neuropathic pain.

• Also, those compounds showed very low pungency profile.

• It can be developed topical cream and gel formulation of TRPV1 agonist.

• The possible applications are Post Herpetic Neuralgia (PHN), Diabetic Peripheral Neuropathy (DPN) and Chemotherapy Induced Neuropathic Pain (CINP) etc.

2. Applications

• Applicable to broad range analgesics on inflammatory pain through neuropathic pain.

• Topical cream and gel formulation possible.

• Intervention area : Post Herpetic Neuralgia (PHN), Diabetic Peripheral Neuropathy (DPN), post operational pain and Chemotherapy Induced Neuropathic Pain (CINP)

3. Market Feasibility

• Pain market size is huge over 100B US$

• Neuropathic pain market is around 4B US$

• Topical analgesics make 1B US$ market

• Novel analgesics for neuropathic pain can expend market size

4. Technical Advantages

• Non of TRPV1 antagonist come out market place

• Several TRPV1 agonist already existed such as capsaicin cream/ patch, zucapsaicin cream

• Capsaicin patch has strong pungency profile. Patient should use Lidocaine as anesthetic before using capsaicin patch, it's very uncomfortable and high cost medicine

• MDFR series compounds showed non pungent and excellent effective topical treatment for neuropathic pain and inflammatory pain

• Broad application of non pungent TRPV1 agonist expected

5. Technical Highlighted Summary

• Less than 2mg/kg dosing, full efficacy showed in formalin test and neuropathic pain model test

• MDFR series compounds did not causing any irritation and edema in mice ear

• MDFR compounds are very much safer than capsaicin

Type of Business Relationship Sought
This program is currently at formulation study for topical administration • Need to collaborate with pain expert global company for formulation • We are seeking partner who are able to collaborate in GLP compliant toxicology study and IND enabling studies together with FTE based collaboration • Out licensing deals for world exclusive sales right except Korea • Licensing deals should along with collaboration
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE